Mission Statement
Anthera Pharmaceuticals is a privately held pharmaceutical company committed to world-class development and commercialization of promising clinical products to address the unmet medical needs of patients with life–threatening inflammatory diseases.
Our Strategy
In order to efficiently commercialize its platform of potent anti-inflammatory products, Anthera has brought together a world-class development team with extensive experience in developing, licensing, and commercializing anti-inflammatory products for unmet medical needs.
Read More
Current Clinical Trials:
Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome
(IMPACTS Trial Site)
Fewer Recurrent Acute
coronary events with Near-term Cardiovascular Inflammation
Suppression
(FRANCIS Trial Site)
Press Releases
May 6‚ 2009
Anthera’s Varespladib Meets Primary Endpoint In Phase 2 Francis Trial For The Treatment Of Acute Coronary Syndrome
March 24‚ 2009
Following Encouraging Results Anthera To Continue Impacts Trial For The Prevention Of Acute Chest Syndrome In Patients With Sickle Cell Disease
January 12‚ 2009
Anthera Announces Enrollment Of 500th Patient In Francis Trial Of A-002 For The Treatment Of Cardiovascular Disease
Anthera Raises Money for Children’s Hospital Oakland Research Institute.
Read More
Anthera has moved! Please note new address and phone number:
25801 Industrial Blvd, Suite B, Hayward, CA 94545 - (510) 856-5600